0001771249-19-000001.txt : 20190320 0001771249-19-000001.hdr.sgml : 20190320 20190320110451 ACCESSION NUMBER: 0001771249-19-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20190320 DATE AS OF CHANGE: 20190320 EFFECTIVENESS DATE: 20190320 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Koligo Therapeutics Ltd CENTRAL INDEX KEY: 0001771249 IRS NUMBER: 000000000 STATE OF INCORPORATION: C3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-335252 FILM NUMBER: 19693967 BUSINESS ADDRESS: STREET 1: LEVEL 5 STREET 2: 126 PHILLIP STREET CITY: SYDNEY STATE: C3 ZIP: 2000 BUSINESS PHONE: 01161292999690 MAIL ADDRESS: STREET 1: LEVEL 5 STREET 2: 126 PHILLIP STREET CITY: SYDNEY STATE: C3 ZIP: 2000 D 1 primary_doc.xml X0708 D LIVE 0001771249 Koligo Therapeutics Ltd LEVEL 5 126 PHILLIP STREET SYDNEY C3 AUSTRALIA 2000 01161292999690 AUSTRALIA None None Corporation true 2018 Peter James Level 5, 126 Phillip Street Sydney NSW C3 AUSTRALIA 2000 Director Matthew Lehman Level 5, 126 Phillip Street Sydney NSW C3 AUSTRALIA 2000 Executive Officer Director Stuart Williams Level 5, 126 Phillip Street Sydney NSW C3 AUSTRALIA 2000 Executive Officer Director Jethro Marks Level 5, 126 Phillip Street Sydney NSW C3 AUSTRALIA 2000 Director Robert Clisdell Level 5, 126 Phillip Street Sydney NSW C3 AUSTRALIA 2000 Director Ariel Sivikofsky Level 5, 126 Phillip Street Sydney NSW C3 AUSTRALIA 2000 Executive Officer Biotechnology $1,000,001 - $5,000,000 06b false 2019-03-12 false true true Koligo Therapeutics, Ltd (Australia) is acquiring Koligo Therapeutics, Inc. (Kentucky, USA). Koligo (Australia) entered into an exchange agreement with the current shareholders of Koligo (Kentucky) to acquire 100% of its issued and outstanding stock. 1500 400000 38000 362000 false 2 0 0 100000 true false Koligo Therapeutics Ltd Matthew Lehman Matthew Lehman CEO 2019-03-20